IGC Pharma, Inc. (IGC) stock
IGCNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q1 FY2027, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 2/3021% above fair value
$0.18−0.01 (-7.24%)
Close on Nov 12, 2026Market cap $19.07MP/E –Yield –
IGC Pharma ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
IGC Pharma's ebitda for the twelve months ending Mar 31, 2026 was -$9.82M. For fiscal 2025 it was -$6.83M. The highest annual figure on record is -$1.66M in fiscal 2017.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2025 | -$6.83M | – |
| FY2024 | Mar 31, 2024 | -$9.16M | – |
| FY2023 | Mar 31, 2023 | -$10.91M | – |
| FY2022 | Mar 31, 2022 | -$14.78M | – |
| FY2021 | Mar 31, 2021 | -$8.25M | – |
| FY2020 | Mar 31, 2020 | -$6.72M | – |
| FY2019 | Mar 31, 2019 | -$4.58M | – |
| FY2018 | Mar 31, 2018 | -$1.77M | – |
| FY2017 | Mar 31, 2017 | -$1.66M | – |
| FY2016 | Mar 31, 2016 | -$2.18M | – |
| FY2015 | Mar 31, 2015 | -$3.56M | – |
| FY2014 | Mar 31, 2014 | -$1.82M | – |
| FY2013 | Mar 31, 2013 | -$1.81M | – |
| FY2012 | Mar 31, 2012 | -$6.52M | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | -$2.40M | – |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | -$2.88M | – |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | -$2.78M | – |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | -$1.76M | – |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | -$1.26M | – |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | -$1.72M | – |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | -$1.62M | – |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | -$2.23M | – |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | -$2.01M | – |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | -$2.84M | – |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | -$2.33M | – |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | -$1.98M | – |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | -$3.89M | – |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | -$2.11M | – |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | -$2.32M | – |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | -$2.64M | – |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | -$6.34M | – |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | -$2.22M | – |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | -$4.19M | – |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | -$2.04M | – |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | -$2.63M | – |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | -$2.20M | – |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | -$1.57M | – |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | -$1.85M | – |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | -$2.37M | – |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | -$1.65M | – |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | -$1.26M | – |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | -$1.44M | – |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | -$1.68M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | -$1.56M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | -$841.00K | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | -$496.00K | – |
| Q4 FY2018CQ1 2018 | Mar 31, 2018 | -$710.00K | – |
| Q3 FY2018CQ4 2017 | Dec 31, 2017 | -$468.00K | – |
| Q2 FY2018CQ3 2017 | Sep 30, 2017 | -$259.00K | – |
| Q1 FY2018CQ2 2017 | Jun 30, 2017 | -$390.31K | – |
| Q4 FY2017CQ1 2017 | Mar 31, 2017 | -$730.37K | – |
| Q3 FY2017CQ4 2016 | Dec 31, 2016 | -$190.01K | – |
See a number that looks wrong?